Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Positioned at the Center of U.S. Copper Security and Policy
The White House’s recent proclamation targets copper imports with tariffs to bolster domestic production and…
-
SuperCom Ltd. (NASDAQ: SPCB) Expands U.S. Footprint with New Wisconsin Project, 12th State in One Year
SuperCom has secured a new electronic monitoring project with a sheriff’s department in Wisconsin, marking…
-
FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy
Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using…